Impressum Bookmark Kontakt Sitemap

Solide Tumoren - Sonstige - CUP - Weiterführende Informationen

CUP

Leitlinien

 

DGHO: www.dgho.de → Leitlinien (G. Hübner, C. Bokemeyer, erstellt 12/05)

 

Studien

 

AIO: www.aio-portal.de/studien, USA/NIH: www.clinicaltrials.gov; in D derzeit Carboplatin/Paclitaxel +/– Cetuximab

 

Ansprechpartner: Sprecher der AG CUP-Syndrom in der AIO, Dr. G. Hübner. E-mail: gerdt.huebner@sana.de.

 

Literatur

 

  • Greco FA et al: Carcinoma of unknown primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy. J Clin Oncol 2011; 29 (suppl): #3563

  • Stoyianni A et al: Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treat Rev 2011; 37: 358–65

  • Thompson DS Et al: Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis. J Clin Oncol 2011; 29(supp): #10560

  • Yi JH et al: Clinical presentation of carcinoma of unknown primary: 14 years of experience. Tumor Biol 2011; 32: 45-51.

  • Ferte C et al: Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. Oncology 2010; 78: 87–93

  • Hainsworth JD et al: Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer 2010; 16: 70–5

  • Hainsworth JD et al: Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010; 116: 2448-54

  • MacReady N: NICE issues guidance on cancer of unknown primary. Lancet Oncol 2010; 11: 824

  • Moller AK et al: Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 2010; 49: 423–30

  • Moller AK et al: Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol 2010; 49: 431–5

  • Monzon FA, Dumur CI: Diagnosis of uncertain primary tumors with the Pathwork tissue-of-origin test. Expert Rev Mol Diagn 2010; 10: 17–25

  • Morawietz L et al: Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Arch 2010; 456: 23–9

  • Park JM et al: The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma. Hum Pathol 2010; 41: 431œ7

  • Pavlidis N et al: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (suppl 5): v228–v31

  • Pentheroudakis G, Pavlidis N: Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 2010; 75: 27–42

  • Hübner G et al: Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009; 100: 44–9

  • Schuette K et al: Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie 2009; 32: 162–6